Portable Low-Volume Therapy for Severe Blood Loss
Abstract
In Year 1 we examined the low concentration end of the full factorial design for our hibernation-based therapy for hemorrhagic shock (Specific Aim 1). We determined that high concentrations of the D-stereoisomer of beta-hydroxybutyrate (D-BHB) are required to improve survival. We also found that the other key component, melatonin, showed therapeutic benefits at concentrations that were 10-fold lower than previously published (Klein et al. 2010). In Year 2 we designed a dose-ranging study to determine if melatonin concentrations could be lowered further and still provide favorable outcomes. Survival curves were compared at 10 days following shock (60% blood loss for 1 hour). Treatments including both BHB and melatonin, even at melatonin concentrations 10-6 lower than previously published, were not statistically different (p > 0.05) from sham-operated animals with no blood loss. Shocked animals that received BHB only, or NaCl with melatonin, survived for statistically shorter times (p < 0.05) than shams. Consistent with Specific Aim 2, we also conducted a semi-log dose range from 0 to 50 mg/kg of 3-iodothyronamine in normotensive animals to corroborate that this thyroid hormone derivative possessed hypothermia-inducing properties. Temperature curves did not differ between treatments (p > 0.05). It is possible that hypothermic effects, if any, are masked by anesthesia. Experiments described in Specific Aim 3 have started, but this work is too preliminary to report in this document.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2013
- Accession Number
- ADA612565
Entities
People
- Cecilia E. Perez De Lara Rodriguez
- Lester R Drewes
- Matthew T Andrews
Organizations
- University of Minnesota Duluth